e6vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For
the month of February 2009
Commission File Number 000-28508
Flamel Technologies S.A.
(Translation of registrants name into English)
Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Indicate by check mark whether registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If Yes is marked, indicate below the file number assigned to the registrant in connection
with Rule 12g3-2(b): 82-
INFORMATION FILED WITH THIS REPORT
Document Index
99.1
Press release regarding appointment of Jeffrey S. Vick as Chief
Business Officer,
dated February 23, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Flamel Technologies S.A. |
|
|
|
|
|
|
|
|
|
Dated:
February 23, 2009
|
|
By:
|
|
/s/ Stephen H. Willard
|
|
|
|
|
Name:
|
|
Stephen H. Willard
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press release regarding appointment of Jeffrey S. Vick as Chief
Business Officer,
dated February 23, 2009. |
exv99w1
Exhibit 99.1
Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer
LYON, France February 23, 2009 Flamel Technologies S.A. (Nasdaq: FLML) today announced that
Jeffery Vick has joined its senior management team as Flamels Chief Business Officer. Mr. Vick
previously served as Chief Executive Officer of Silence Therapeutics plc, a leading European RNAi
company. Mr. Vick received his MBA from Stanford University, his MS in Chemistry from the
University of California, San Diego, and brings to Flamel over twenty years experience in the
pharmaceutical and biotechnology industries.
Jeffs expertise in corporate development, market research, and intellectual property issues has
been developed both in Europe and in the U.S., remarked Stephen H. Willard, the Companys chief
executive officer. His background in these areas, together with his history of doing fundamental
research in oncology and his work in developing biotechnology, drug delivery and genomics
companies, makes him an ideal addition to the Flamel team. My colleagues and I are greatly looking
forward to Jeffs assistance in building upon Flamels existing relationships with our
pharmaceutical and biotechnology partners and in developing new ones.
Flamels technology platforms are ideally positioned to provide important solutions to the
pharmaceutical and biotechnology industries. These extend to efficacy and safety, but also to
important issues in drug development such as stabilization and the extension of effective half-life
without affecting bioactivity, said Mr. Vick. I am particularly pleased to be joining a company
which enjoys tremendous growth opportunities coupled with a solid financial foundation.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled
release and taste-masking technology for the oral administration of small molecule drugs. Flamels
Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins
and peptides.
Contact:
Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE: + 33-4-72-78-34-34
Marlio@flamel.com
This document contains a number of matters, particularly as related to the status of various
research projects and technology platforms, that constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current
view of management with respect to future events and is subject to risks and uncertainties that
could cause actual results to differ materially from those contemplated in such forward-looking
statements. These risks include risks that products in the development stage may not achieve
scientific objectives or milestones or meet stringent regulatory requirements, uncertainties
regarding market acceptance of products in development, the impact of competitive products and
pricing, and the risks associated with Flamels reliance on outside parties and key strategic
alliances. These and other risks are described more fully in Flamels Annual Report on the
Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.